Double trouble for prostate cancer: synergistic action of AR blockade and PARPi in non-HRR mutated patients

Prostate cancer (PCa) is the most common cancer in men worldwide. Despite better and more intensive treatment options in earlier disease stages, a large subset of patients still progress to metastatic castration-resistant PCa (mCRPC). Recently, poly-(ADP-ribose)-polymerase (PARP)-inhibitors have bee...

Descripción completa

Detalles Bibliográficos

Autores principales:	Alexander Giesen, Loïc Baekelandt, Wout Devlies, Gaëtan Devos, Herlinde Dumez, Wouter Everaerts, Frank Claessens, Steven Joniau
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Frontiers Media S.A. 2023-09-01
Colección:	Frontiers in Oncology
Materias:	prostate cancer HRR genes synergistic effect (combined treatment) PARP inhibition (PARPi) androgen receptor signaling inhibitor
Acceso en línea:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1265812/full
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!